Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 7/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888473 | 0.88 | TGFBR1 (0.38) | TGFBR1MAPK14LMNA | |
| SCHEMBL3838556 | 0.77 | TGFBR1 (0.47) | TGFBR1ACVRL1ACVR1BACVR1BMPR1A | |
| SCHEMBL24568790 | 0.76 | HPGD (0.44) | LMNAHTTKMO | |
| SCHEMBL18015820 | 0.75 | HTR1B (0.43) | TGFBR1PTGESHSD11B1KMO | |
| SCHEMBL16879402 | 0.73 | TGFBR1 (0.39) | TGFBR1ACVRL1ACVR1BACVR1KMO | |
| SCHEMBL28115668 | 0.72 | TGFBR1 (0.51) | TGFBR1ACVRL1ACVR1BACVR1BMPR1A | |
| SCHEMBL84107 | 0.72 | LMNA (0.47) | TGFBR1LMNATP53HTT | |
| SCHEMBL30426282 | 0.70 | HSD11B1 (0.41) | TGFBR1HTTHSD11B1 | |
| SCHEMBL18368368 | 0.70 | LMNA (0.33) | LMNA | |
| SCHEMBL24569030 | 0.70 | AGPAT2 (0.38) | TGFBR1PTGESHSD11B1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| EP-3089971-A1 | COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103355-A1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVRL1 197/4885ACVR1B 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.